TY - JOUR
T1 - Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases
T2 - The case of genetic CJD
AU - Mizrahi, Michal
AU - Friedman-Levi, Yael
AU - Larush, Liraz
AU - Frid, Kati
AU - Binyamin, Orli
AU - Dori, Dvir
AU - Fainstein, Nina
AU - Ovadia, Haim
AU - Ben-Hur, Tamir
AU - Magdassi, Shlomo
AU - Gabizon, Ruth
N1 - Funding Information:
Funding: This project was funded by a grant from the Israel Science Foundation (ISF) and by the Agnes Ginges Center. At present time, a commercial entity (Granalix) is being formed based on the presented results
PY - 2014/8
Y1 - 2014/8
N2 - Neurodegenerative diseases generate the accumulation of specific misfolded proteins, such as PrPSc prions or A-beta in Alzheimer's diseases, and share common pathological features, like neuronal death and oxidative damage. To test whether reduced oxidation alters disease manifestation, we treated TgMHu2ME199K mice, modeling for genetic prion disease, with Nano-PSO, a nanodroplet formulation of pomegranate seed oil (PSO). PSO comprises large concentrations of a unique polyunsaturated fatty acid, Punicic acid, among the strongest natural antioxidants. Nano-PSO significantly delayed disease presentation when administered to asymptomatic TgMHu2ME199K mice and postponed disease aggravation in already sick mice. Analysis of brain samples revealed that Nano-PSO treatment did not decrease PrPSc accumulation, but rather reduced lipid oxidation and neuronal loss, indicating a strong neuroprotective effect. We propose that Nano-PSO and alike formulations may be both beneficial and safe enough to be administered for long years to subjects at risk or to those already affected by neurodegenerative conditions. From the Clinical Editor: This team of authors report that a nanoformulation of pomegranade seed oil, containing high levels of a strong antioxidant, can delay disease onset in a mouse model of genetic prion diseases, and the formulation also indicates a direct neuroprotective effect.
AB - Neurodegenerative diseases generate the accumulation of specific misfolded proteins, such as PrPSc prions or A-beta in Alzheimer's diseases, and share common pathological features, like neuronal death and oxidative damage. To test whether reduced oxidation alters disease manifestation, we treated TgMHu2ME199K mice, modeling for genetic prion disease, with Nano-PSO, a nanodroplet formulation of pomegranate seed oil (PSO). PSO comprises large concentrations of a unique polyunsaturated fatty acid, Punicic acid, among the strongest natural antioxidants. Nano-PSO significantly delayed disease presentation when administered to asymptomatic TgMHu2ME199K mice and postponed disease aggravation in already sick mice. Analysis of brain samples revealed that Nano-PSO treatment did not decrease PrPSc accumulation, but rather reduced lipid oxidation and neuronal loss, indicating a strong neuroprotective effect. We propose that Nano-PSO and alike formulations may be both beneficial and safe enough to be administered for long years to subjects at risk or to those already affected by neurodegenerative conditions. From the Clinical Editor: This team of authors report that a nanoformulation of pomegranade seed oil, containing high levels of a strong antioxidant, can delay disease onset in a mouse model of genetic prion diseases, and the formulation also indicates a direct neuroprotective effect.
KW - Nanoparticles
KW - Neurodegeneration
KW - Oxidation
KW - PSO
KW - Prion
UR - http://www.scopus.com/inward/record.url?scp=84905254678&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2014.03.015
DO - 10.1016/j.nano.2014.03.015
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24704590
AN - SCOPUS:84905254678
SN - 1549-9634
VL - 10
SP - 1353
EP - 1363
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 6
ER -